

OG Pathway Board - Action Log and Summary

Log No.	Date Created	Status	Discussion summary	Action	Action Lead	Update
21	14.01.21	Closed	<p>Title: Housekeeping/Introductions/Action Log To: Discuss & Agree Owner: JS JS welcomed everyone to the meeting and requested to remain on mute if you are not talking. JS advised future meetings will ideally be face to face (F2F), with the subgroups meetings being held between 9am and 10am. ZM presented action log from previous PWB – this was accepted without comment.</p>	For information only, no action noted		
12	14.01.21	Open	<p>Title: Research and Immunotherapies - To: Discuss Owner: WM WM previously presented MSI status. MSI testing is another way of seeing how patients will respond to immuno oncology treatment and chemotherapy, knowing the status, guides their treatment with patient outcomes from 8.8 months to 14 months and as a summary there will be a change in standards of care coming. UPDATE : NICE guidance and NHSE interim guidance have approved the drug but not the test to find out who needs the drug. SS reported back that a number of pathway boards are also requesting similar tissue samples and with this in mind, the same process has been agreed to look at this going forward. This is to firstly gain clinical consensus in the pathway board and then to approach each Trust to ask if this already done. IF Trusts require funding, then to come back to the board. In terms of research update in general - Manchester stopped recruiting to trials due to the pandemic which is something we need to learn from.</p>	<p>Pathway Board members are in support. Genomics PWB are taking this forward as some tissue samples are already funded nationally. WM, SH to incorporate HER 2 and MSI within GM pathology guidance with covering letter. SS, WM, JS and SH to meet.</p>	JS	
	14.01.21	Open	<p>Title: GM Pathology Guidance To: Approval Owner: SH Guidance has been gone out to pathologists in the region and well received incorporating the HER 2 testing.</p>	<p>Add MSI testing to the guidance WM to add wording to the document to go to Trust Directors. Document approved</p>	WM/FL	
	14.01.21	Open	<p>Title: Research To: Update Owner: WM WM gave an update on the types of research happening (or not happening) in GM and some of the issues. Multi factorial reasons but identificaiotn of patients needs to be earlier, some of the issues are that surgery is discussed as an option before organ perservation has been discussed so patients are opting for surgery. Hopefully the Assessment clinic will help but the presence of oncology is very sad to hear from a GM perspective. The study poster was not available in time for this meeting, but the NIHR report is all we recieve. EH asked when the patient is informed of potential trials? Ifusinf EQIPOISE, for example, surgery is offered surgery, it is very difficult to persuade a patient that there are other options that can be as effective. The feedback from the small communities about choice is they are aware that there is choice and the treatment has already been decided and patients are guided by experts.</p>	<p>Off line discussion re Trials to be had - JS/WM. Convene meeting with UI, surgeons etc to improve</p>	JS/WM	